ArticleEuropean radiology2025
Temporal evolution of the LI-RADS radiation treatment response assessment on multiphase CT/MRI in patients undergoing selective internal radiation therapy for hepatocellular carcinoma.
Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Prognostic Impact of Arterial Phase Hyperenhancement After Proton Beam Therapy for Untreated Solitary Hepatocellular Carcinoma.Cancer medicine · 2026Article
- Prognostic Value of MRI-Based Treatment Response Assessment Criteria in Hepatocellular Carcinoma After Stereotactic Body Radiotherapy: A Comparative Analysis of mRECIST, LI-RADS TRA Version 2017, and LI-RADS Radiation TRA Version 2024.Journal of magnetic resonance imaging : JMRI · 2026Article
- The value ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Editorial for "Prognostic Value of MRI-Based Treatment Response Assessment Criteria in Hepatocellular Carcinoma After Stereotactic Body Radiotherapy: A Comparative Analysis of mRECIST, LI-RADS TRA Version 2017, and LI-RADS Radiation TRA Version 2024".Journal of magnetic resonance imaging : JMRI · 2026Article
- Prognostic factors and treatment response in previously treated hepatocellular carcinoma patients receiving Y-90 radioembolization combined with targeted-immunotherapy: an exploratory analysis.Abdominal radiology (New York) · 2026Article
- The 2024 LI-RADS treatment response update: practical reporting after non-radiation and radiation locoregional therapies for hepatocellular carcinoma.Insights into imaging · 2026Review
- Role of MRI in Imaging Assessment of Radiation-Based Treatment of Hepatocellular Carcinoma.Cancers · 2026Review
- Analysis of risk factors and prediction of prognosis in patients with primary liver cancer undergoing transarterial chemoembolization.Frontiers in oncology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess the temporal evolution and interobserver agreement of the early categories per the liver imaging reporting and data system (LI-RADS) radiation treatment response assessment (TRA) algorithm in patients receiving selective internal radiation therapy (SIRT) with Yttrium-90 for hepatocellular carcinoma (HCC). MATERIALS AND
methodsThis single-center retrospective study included consecutive patients with treatment-naïve HCC who underwent serial contrast-enhanced CT/MRI before and after SIRT. Three masked radiologists independently evaluated response at 3-6 months. Another senior radiologist assessed response at 9, 12, 15, 18, 21, 24, and > 24 months after comprehensive review of available clinical-radiological information.
results65 patients (mean age, 66.7 ± 11.2 years; 48 men) were included. At 3-6 months after SIRT, 47.7% (31/65) of lesions were assigned to the nonprogressing category, and the remaining 52.3% (34/65) to the nonviable category. Among early nonprogressing lesions, 64.5% (20/31) regressed to the nonviable category, 25.8% (8/31) remained nonprogressing, and 9.7% (3/31) evolved into the viable category at ≥ 12 months. The nonprogressing category decreased in number over time, with 61.3% (19/31) conversion to the nonviable category at 9 months. Among the early nonviable lesions, 91.2% (31/34) remained nonviable at ≥ 12 months, and 8.8% (3/34) evolved into the viable category. Agreement for the 3-6 months LR-TR category assignment was moderate (kappa = 0.46) with CT but almost perfect (kappa = 0.85) with MRI.
conclusionsSIRT induced a delayed and sustained response in the majority of HCC patients after ≥ 12 months. MRI demonstrated superior agreement over CT in assessing response at 3-6 months. KEY POINTS: Question Tumor response to SIRT can change; there is limited evidence on the evolution of the imaging appearance of HCC following SIRT. Findings Sixty-four and five-tenths of early nonprogressing lesions regressed to nonviable, and 91.2% of early nonviable lesions remained free of viability. LR-TR category assignment agreement was moderate with CT but almost perfect with MRI. Clinical relevance SIRT induced a delayed and sustained response in HCC, underscoring the necessity of dynamic evaluation of long-term changes in treated lesions. MRI with subtraction imaging may be preferred over CT for long-term monitoring, which may help prevent premature retreatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.